New Journal Website is available at:

Published by: Kowsar

Hormonal Profile in Patients With Dilated Cardiomyopathy

Nasim Naderi 1 , * , Mona Heidarali 1 , Fatemeh Barzegari 1 , Behshid Ghadrdoost 1 , Ahmad Amin 1 and Sepideh Taghavi 1
Authors Information
1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Research in Cardiovascular Medicine: August 2015, 4 (3); e27631
  • Published Online: August 1, 2015
  • Article Type: Research Article
  • Received: February 2, 2015
  • Revised: April 29, 2015
  • Accepted: May 3, 2015
  • DOI: 10.5812/cardiovascmed.27631v2

To Cite: Naderi N, Heidarali M, Barzegari F, Ghadrdoost B, Amin A, et al. Hormonal Profile in Patients With Dilated Cardiomyopathy, Res Cardiovasc Med. 2015 ;4(3):e27631. doi: 10.5812/cardiovascmed.27631v2.

Copyright: Copyright © 2015, Research in Cardiovascular Medicine. .
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14(8): 803-69[DOI][PubMed]
  • 2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DJ, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16)-239[DOI][PubMed]
  • 3. Laragh JH. Hormones and the pathogenesis of congestive heart failure: vasopressin, aldosterone, and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis. Circulation. 1962; 25: 1015-23[PubMed]
  • 4. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997; 96(2): 526-34[PubMed]
  • 5. Sacca L. Heart Failure as a Multiple Hormonal Deficiency Syndrome. Circ Heart Fail. 2009; 2(2): 151-6[DOI]
  • 6. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol. 2003; 87(2-3): 179-83[DOI]
  • 7. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996; 334(13): 809-14[DOI][PubMed]
  • 8. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001; 38(2): 443-52[DOI]
  • 9. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007; 116(15): 1725-35[DOI][PubMed]
  • 10. Schmidt-Ott UM, Ascheim DD. Thyroid hormone and heart failure. Curr Heart Fail Rep. 2006; 3(3): 114-9[PubMed]
  • 11. Ascheim DD, Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid. 2002; 12(6): 511-5[DOI][PubMed]
  • 12. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012; 126(9): 1040-9[DOI][PubMed]
  • 13. Opalinska-Ciszek E, Niemczyk S, Matuszkiewicz-Rowinska J. [Prolactin (PRL), thyrotropin (TSH), free thyroid hormones (fT4), (fT3) and testosterone (TTE) level in men with chronic heart failure]. Pol Arch Med Wewn. 2005; 113(4): 320-5[PubMed]
  • 14. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006; 27(1): 57-64[DOI][PubMed]
  • 15. Sarkar NN. Hormonal profiles behind the heart of a man. Cardiol J. 2009; 16(4): 300-6[PubMed]
  • 16. Naderi N, Bakhshandeh H, Barzegari F, Amin A, Taghavi S, Maleki M. Hyper-Prolactinemia in Men with Idiopathic Dilated Cardiomyopathy: Does it Have any Prognostic Implications? Res Cardiovasc Med. 2014; 3(3)[DOI]
  • 17. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008; 93(4): 1351-8[DOI][PubMed]
  • 18. Nanchen D, Gussekloo J, Westendorp RG, Stott DJ, Jukema JW, Trompet S, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab. 2012; 97(3): 852-61[DOI][PubMed]
  • 19. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010; 122(4): 385-93[DOI][PubMed]
  • 20. Wollert K. Growth hormone and proinflammatory cytokine activation in heart failure Just a new verse to an old sirens' song? Eur Heart J. 2003; 24(24): 2164-5[DOI]
  • 21. Hambrecht R, Schulze PC, Gielen S, Linke A, Winkler S, Erbs S, et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2005; 12(4): 401-6[DOI]
  • 22. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003; 9(3): 219-26[DOI][PubMed]
  • 23. Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. J Clin Endocrinol Metab. 2007; 92(1): 180-5[DOI][PubMed]
  • 24. Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab. 2009; 94(9): 3329-36[DOI][PubMed]
  • 25. Cittadini A, Marra AM, Arcopinto M, Bobbio E, Salzano A, Sirico D, et al. Growth Hormone Replacement Delays the Progression of Chronic Heart Failure Combined With Growth Hormone Deficiency. JACC. 2013; 1(4): 325-30[DOI]
  • 26. Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BA. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J. 1998; 19(11): 1704-11[PubMed]
  • 27. Agarwal M, Naghi J, Philip K, Phan A, Willix RJ, Schwarz ER. Growth hormone and testosterone in heart failure therapy. Expert Opin Pharmacother. 2010; 11(11): 1835-44[DOI][PubMed]
  • 28. Adamopoulos S, Parissis JT, Georgiadis M, Karatzas D, Paraskevaidis J, Kroupis C, et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J. 2002; 144(2): 359-64[PubMed]
  • 29. Pugh P. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003; 24(10): 909-15[DOI]
  • 30. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004; 90(4): 446-7[PubMed]
  • 31. Wickramatilake CM, Mohideen MR, Pathirana C. Testosterone: a promising adjuvant for a failing heart? J Ceylon Coll Physicians. 2012; 42(1-2)[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader